Quantcast
Home > Quotes > MBRX

Moleculin Biotech, Inc. Common Stock (MBRX) Quote & Summary Data

MBRX 
$1.665
*  
0.035
2.15%
Get MBRX Alerts
*Delayed - data as of Sep. 18, 2018  -  Find a broker to begin trading MBRX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 1.63 / $ 1.78
1 Year Target
8
Today's High / Low
$ 1.69 / $ 1.62
Share Volume
106,527
50 Day Avg. Daily Volume
113,009
Previous Close
$ 1.63
52 Week High / Low
$ 3.34 / $ 1.50
Market Cap
44,724,393
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.68

Intraday Chart

Shares Traded

Share Volume:
106,527
50 Day Avg. Daily Volume:
113,009

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.58

Trading Range

The current last sale of $1.665 is 11.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.69 $ 3.34
 Low: $ 1.62 $ 1.50

Company Description (as filed with the SEC)

MBI is a clinical-stage pharmaceutical company organized as a Delaware corporation in July 2015 to focus on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as "MD Anderson". MBI has three core drug technologies: a uniquely designed anthracycline (Annamycin), a portfolio of STAT3 inhibitors (WP1066 Portfolio) and a collection of inhibitors of glycolysis (WP1122 Portfolio). Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.  ... More ...  


Risk Grade

Where does MBRX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.63
Open Date:
Sep. 18, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info